Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen

AIDS Research and Therapy

Volumn 2, Issue 1, 2005, Pages

  Baird, Heather A ^a   Marozsan, Andre J ^a   Lederman, Michael M ^a   Landay, Alan ^b   Mildvan, Donna ^c   Kuritzkes, Daniel R ^d   Kessler, Harold A ^b   Arts, Eric J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HIV 1; p24 antigen capture; Protease inhibitors

Indexed keywords

ABACAVIR; CAPSID PROTEIN; CD4 ANTIGEN; GAG PROTEIN; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEIN P55; PROTEIN PRECURSOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INHIBITION KINETICS; LYMPHOCYTE COUNT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULTRACENTRIFUGATION; VIROGENESIS; VIRUS PARTICLE; VIRUS VIRULENCE;

EID: 33845194705     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-2-2     Document Type: Article

References (20)

1. Arts EJ, Mak J, Kleiman L, Wainberg MA: DNA found in human immunodeficiency virus type 1 particles may not be required for infectivity. J Gen Virol 1994, 75(Pt 7):1605-1613.
2. Arts EJ, Mak J, Kleiman L, Wainberg MA: Mature reverse transcriptase (p66/p51) is responsible for low levels of viral DNA found in human immunodeficiency virus type 1 (HIV-1). Leukemia 1994, 8(Suppl 1):S175-S178.
3. Arts EJ, Wainberg MA: Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 1996, 40:527-540.
4. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B: An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A 1990, 87:7472-7476.
5. Coffin JM: Retroviridae: The viruses and their replication. Fundamental Virology 1996:763-843.
6. Lambert DM, Petteway SR Jr, McDanal CE, Hart TK, Leary JJ, Dreyer GB, Meek TD, Bugelski PJ, Bolognesi DP, Metcalf BW, et al.: Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother 1992, 36:982-988.
7. Landay AL, Spritzler J, Kessler H, Mildvan D, Pu M, Fox L, Kuritzkes D, Ledeman MM: Immune Reconstitution Is Comparable in Antiretroviral (ARV) Naive Subjects Following 1 Year of Therapy with a Nucleoside Reverse Transcriptase Inhibitor (NRTI) or Protease Inhibitor (PI) Containing ARV Regimen. J Infect Dis 2003, 188(10):1444-54.
8. Liegler TJ, Grant RM: HIV Viral Load Assay. UCSF. 2003 [http://hivinsite.ucsf.edu/InSite.jsp?page=kb-02-02-02-01].
9. Lori F, M di V, de Vico AL, Lusso P, Reitz MS Jr, Gallo RC: Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol 1992, 66:5067-5074.
10. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
11. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, et al.: Inhibition of HIV-1 replication by a nonnucleoside reverse transciptase inhibitor. Science 1990, 250:1411-1413.
12. Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, Jadhav PK, Patterson CE, Hodge CN, Cheng YS: In vitro isolation and identification of human immunodeficiency virus (HIV) variants wth reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A 1993, 90:7543-7547.
13. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
14. Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J: Human immunodeficiency virus type 1 mustants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A 1991, 88:11241-11245.
15. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, CM Chen, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Norbeck DW: ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998, 42:3218-3224.
16. Swanstrom R, Wills JW: Synthesis, Assembly, and Processing of Viral Proteins. Retroviruses 1997:205-334.
17. Trono D: Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol 1992, 66:4893-4900.
18. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Shaw G: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
19. Blankson JN, Finzi D, Pierson TC, Sabundayo BP, Chadwick K, Margolick JB, Quinn TC, Siliciano RF: Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000, 182(6):1636-42.
20. Perelson AS, Essunger P, Cao Y, Vasanen M, Hurley A, Saksela K, Markowitz M, DHo D: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387(6629):188-191.